Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gen Sobue

Showing results (461-470 of 576) with videos related to

Pageof 58
Sort By:
Parkinsonism & Related Disorders|November 9, 2021
Instability of speech in Parkinson disease patients with subthalamic nucleus deep brain stimulationYasuhiro Tanaka, Takashi Tsuboi, Hirohisa Watanabe, et al.
Plos One|July 5, 2013
Ablation of keratan sulfate accelerates early phase pathogenesis of ALSKenichi Hirano, Tomohiro Ohgomori, Kazuyoshi Kobayashi, et al.
Brain : a Journal of Neurology|July 26, 2013
Clinicopathological features of neuropathy associated with lymphomaMinoru Tomita, Haruki Koike, Yuichi Kawagashira, et al.
Neurobiology of Aging|May 27, 2011
Partial impairment of c-Ret at tyrosine 1062 accelerates age-related hearing loss in miceNobutaka Ohgami, Michiru Ida-Eto, Naomi Sakashita, et al.
Human Molecular Genetics|March 11, 2016
A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophyLaura C Bott, Nisha M Badders, Ke-Lian Chen, et al.
Plos One|December 23, 2016
Decreased Peak Expiratory Flow Associated with Muscle Fiber-Type Switching in Spinal and Bulbar Muscular AtrophyShinichiro Yamada, Atsushi Hashizume, Yasuhiro Hijikata, et al.
Journal of the Peripheral Nervous System : JPNS|January 24, 2019
Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra studyOrell Mielke, Vera Bril, David R Cornblath, et al.
Molecular Therapy. Nucleic Acids|February 23, 2023
Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS/FTD miceToshihide Takeuchi, Kazuhiro Maeta, Xin Ding, et al.
Nature Communications|May 14, 2015
FUS regulates AMPA receptor function and FTLD/ALS-associated behaviour via GluA1 mRNA stabilizationTsuyoshi Udagawa, Yusuke Fujioka, Motoki Tanaka, et al.
BMJ Open|January 10, 2015
Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trialKanako Katayama, Sonoko Misawa, Yasunori Sato, et al.
Pageof 58

Showing results (461-470 of 576) with videos related to

Sort By:
Pageof 58
Parkinsonism & Related Disorders|November 9, 2021
Instability of speech in Parkinson disease patients with subthalamic nucleus deep brain stimulationYasuhiro Tanaka, Takashi Tsuboi, Hirohisa Watanabe, et al.
Plos One|July 5, 2013
Ablation of keratan sulfate accelerates early phase pathogenesis of ALSKenichi Hirano, Tomohiro Ohgomori, Kazuyoshi Kobayashi, et al.
Brain : a Journal of Neurology|July 26, 2013
Clinicopathological features of neuropathy associated with lymphomaMinoru Tomita, Haruki Koike, Yuichi Kawagashira, et al.
Neurobiology of Aging|May 27, 2011
Partial impairment of c-Ret at tyrosine 1062 accelerates age-related hearing loss in miceNobutaka Ohgami, Michiru Ida-Eto, Naomi Sakashita, et al.
Human Molecular Genetics|March 11, 2016
A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophyLaura C Bott, Nisha M Badders, Ke-Lian Chen, et al.
Plos One|December 23, 2016
Decreased Peak Expiratory Flow Associated with Muscle Fiber-Type Switching in Spinal and Bulbar Muscular AtrophyShinichiro Yamada, Atsushi Hashizume, Yasuhiro Hijikata, et al.
Journal of the Peripheral Nervous System : JPNS|January 24, 2019
Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra studyOrell Mielke, Vera Bril, David R Cornblath, et al.
Molecular Therapy. Nucleic Acids|February 23, 2023
Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS/FTD miceToshihide Takeuchi, Kazuhiro Maeta, Xin Ding, et al.
Nature Communications|May 14, 2015
FUS regulates AMPA receptor function and FTLD/ALS-associated behaviour via GluA1 mRNA stabilizationTsuyoshi Udagawa, Yusuke Fujioka, Motoki Tanaka, et al.
BMJ Open|January 10, 2015
Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trialKanako Katayama, Sonoko Misawa, Yasunori Sato, et al.
Pageof 58